Sourced from Nektar Therapeutics (NKTR) SEC filings. All data provided as-is without any warranty. Check original SEC filings before making any investment decision.
Nektar Therapeutics Income Statement
Sales or Revenue:
SG&A Expense:
Research & Development:
Operating Income:
Operating Expenses:
Non Operating Income/Expense:
Net Income:
Investment Income Interest And Dividend:
Cost Of Goods Sold incl. D&A:
Depreciation & Amortization Expense:
EPS (Diluted):
Basic Shares Outstanding:
EPS (Basic):
Diluted Shares Outstanding:
Nektar Therapeutics Cash Flow
Proceeds from Issuance of Long-term Debt:
Payments to Acquire Property, Plant, and Equipment:
Payments to Acquire Businesses, Net of Cash Acquired:
Payments Related to Tax Withholding for Share-based Compensation:
Payments of Dividends:
Payments for Repurchase of Common Stock:
Net Cash Provided by (Used in) Operating Activities:
Net Cash Provided by (Used in) Investing Activities:
Net Cash Provided by (Used in) Financing Activities:
Increase (Decrease) in Other Receivables:
Increase (Decrease) in Other Operating Liabilities:
Increase (Decrease) in Other Operating Assets:
Increase (Decrease) in Inventories:
Increase (Decrease) in Deferred Revenue:
Increase (Decrease) in Accounts Receivable:
Increase (Decrease) in Accounts Payable:
Income Tax Expense (Benefit):
Cash and Cash Equivalents, Period Increase (Decrease):